Coherus BioSciences: Pure Play In The Emerging Biosimilar In Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coherus BioSciences: Pure Play In The Emerging Biosimilar In

CHRS 1.670

-1.5%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: DewDiligence_on_SI	2/11/2015 8:31:18 PM
	Read Replies (2) of 9

CHRS’ Leerink webcast has a good discussion of the pros and cons of the 351(k) pathway versus a conventional BLA.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next